Nemus Bioscience announced an agreement with Noramco for the manufacturing and scale-up of proprietary analog of cannabidiol (CBD) licensed from the University of Mississippi.
Noramco, a leader in controlled substances and cannabinoids, is adding commercial-scale capacity of dronabinol (THC) at its Athens, Georgia, United States facility. The expansion comes in response to rising demand for its highly pure cannabidiol (CBD) and dronabinol (THC) analogs of cannabis sativa.
Noramco, a global leading producer of controlled substances, including cannabinoids for the pharmaceutical industry, today announced that it has filed a provisional patent application with the US Patent and Trademark Office (USPTO) directed to its proprietary pure cannabidiol (CBD) compositions.
Noramco is moving forward with a broad offering of clinical- to commercial-scale cannabinoid APIs for branded and generic pharmaceuticals. The comprehensive offering includes everything a drug manufacturer requires to advance cannabinoid-based APIs to finished dosage forms.